Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 4 | 1 |
| List of Figures | 5 | 1 |
| BioTime, Inc., Medical Equipment, Deals By Year, 2010 to YTD 2016 | 5 | 2 |
| BioTime, Inc., Medical Equipment Deals By Type, 2010 to YTD 2016 | 7 | 1 |
| BioTime, Inc., Medical Equipment, Deals By Region, 2010 to YTD 2016 | 8 | 1 |
| BioTime, Inc., Medical Equipment, Deals By Market, 2010 to YTD 2016 | 9 | 1 |
| BioTime, Inc., Medical Equipment, Deals Summary, 2010 to YTD 2016 | 10 | 2 |
| BioTime, Inc., Medical Equipment, Deal Details | 12 | 30 |
| Venture Financing | 12 | 1 |
| LifeMap Solutions Raises US$5 Million In Seed Financing | 12 | 1 |
| Glycosan BioSystems Raises US$0.6 Million In Venture Financing | 13 | 1 |
| Partnerships | 14 | 1 |
| OncoCyte Enters into Licensing Agreement with Cornell University for PanC-Dx | 14 | 1 |
| OncoCyte Enters into Co-Development Agreement with Abcodia for PanC-Dx Test | 15 | 1 |
| OncoCyte Expands Co-Development Agreement with Wistar Institute | 16 | 1 |
| BioTime Enters Into Distribution Agreement With USCN Life Science | 17 | 1 |
| OncoCyte Enters into Licensing Agreement with Wistar Institute of Anatomy and Biology | 18 | 2 |
| Heraeus Medical Enters into Licensing Agreement with OrthoCyte | 20 | 1 |
| Biotime Amends Licensing Agreement With University of Utah | 21 | 1 |
| BioTime Enters Into Option Licensing Agreement With USCN Life Science | 22 | 1 |
| Equity Offering | 23 | 1 |
| OncoCyte Raises USD3.2 Million in Private Placement of Units | 23 | 2 |
| OncoCyte Raises USD7.3 Million in Private Placement of Units | 25 | 1 |
| BioTime Raises USD5 Million in Private Placement of Shares | 26 | 2 |
| OncoCyte Raises USD3.3 Million in Private Placement of Shares | 28 | 1 |
| BioTime Completes Private Placement Of Shares For US$6.4 Million | 29 | 1 |
| BioTime Announces Public Offering Of Shares For Up To US$15 Million | 30 | 1 |
| BioTime Completes Public Offering Of Shares For US$3.5 Million | 31 | 1 |
| BioTime Completes Private Placement Of Units For US$9 Million | 32 | 2 |
| BioTime Accelerates Closing Date For Second Tranche Of Private Placement Of Shares For US$3 Million | 34 | 2 |
| BioTime Announces Private Placement Of Common Stock | 36 | 1 |
| BioTime Completes Private Placement For US$3.6 Million | 37 | 1 |
| Acquisition | 38 | 1 |
| OrthoCyte Completes Acquisition Of Glycosan BioSystems | 38 | 2 |
| BioTime Acquires ES Cell International | 40 | 2 |
| BioTime, Inc. - Key Competitors | 42 | 1 |
| Key Employees | 43 | 1 |
| Locations And Subsidiaries | 44 | 2 |
| Head Office | 44 | 1 |
| Other Locations &Subsidiaries | 44 | 2 |
| Recent Developments | 46 | 1 |
| Financial Announcements | 46 | 1 |
| Aug 09, 2016: BioTime Reports Second Quarter Results and Recent Corporate Accomplishments | 46 | 2 |
| May 10, 2016: BioTime Reports First Quarter Results and Recent Corporate Accomplishments | 48 | 3 |
| Nov 09, 2015: BioTime Reports Third Quarter 2015 Results and Recent Corporate Accomplishments | 51 | 4 |
| Aug 10, 2015: BioTime Reports Second Quarter 2015 Results and Recent Developments | 55 | 3 |
| May 11, 2015: BioTime Reports First Quarter 2015 Results and Recent Corporate Accomplishments | 58 | 2 |
| May 07, 2015: Asterias Biotherapeutics Reports First Quarter Results | 60 | 1 |
| Mar 11, 2015: BioTime Reports Fourth Quarter and Fiscal Year End 2014 Financial Results and Recent Corporate Accomplishments | 61 | 2 |
| Corporate Communications | 63 | 1 |
| Dec 30, 2015: BioTime Announces When-Issued Trading of Subsidiary OncoCyte in Connection With Planned Distribution | 63 | 1 |
| Nov 18, 2015: BioTime Announces the Appointment of Life Sciences Industry Veteran Russell Skibsted as Chief Financial Officer | 64 | 1 |
| Oct 19, 2015: Adi Mohanty Joins Michael D. West, PhD, as Co-CEO of BioTime | 65 | 1 |
| Sep 14, 2015: BioTime Subsidiary OncoCyte Appoints Cavan Redmond to its Board of Directors | 66 | 1 |
| Jun 16, 2015: William Annett Named Chief Executive Officer of OncoCyte | 67 | 1 |
| Jan 12, 2015: BioTime Subsidiary OncoCyte Appoints William Annett to Its Board of Directors | 68 | 1 |
| Product News | 69 | 1 |
| Apr 20, 2015: OncoCyte Announces Initial Data From Ongoing Clinical Study of Collagen Type X as a Marker and Potential Diagnostic for Breast Cancer and Other Types of Human Cancers | 69 | 1 |
| Apr 20, 2015: Positive Clinical Results of OncoCyte s PanC-Dx Diagnostic Test Demonstrate High Level of Sensitivity and Specificity in Non-Invasive Detection of Bladder Cancer | 70 | 1 |
| Mar 20, 2015: OncoCyte Announces Availability of Abstracts With New Clinical Data From Studies of PanC-Dx Cancer Diagnostic in Bladder | 71 | 1 |
| Mar 20, 2015: OncoCyte Announces Availability of Abstracts With New Clinical Data From Studies of PanC-Dx Cancer Diagnostic in Breast Cancer | 72 | 1 |
| Feb 24, 2015: BioTime Announces First Patient Treated in Pivotal Clinical Trial of Renevia for HIV-Associated Lipoatrophy | 73 | 2 |
| Clinical Trials | 75 | 1 |
| Feb 24, 2015: BioTime Announces First Patient Treated in Pivotal Clinical Trial of Renevia for HIV-Associated Lipoatrophy | 75 | 2 |
| Other Significant Developments | 77 | 1 |
| Jan 27, 2015: ESI BIO - A Division of BioTime Announces New UK Distribution Agreement with 2BScientific | 77 | 1 |
| Appendix | 78 | 1 |
| Methodology | 78 | 1 |
| About GlobalData | 78 | 1 |
| Contact Us | 78 | 1 |
| Disclaimer | 78 | 1 |